Last reviewed · How we verify
Ventoline® Evohaler® 100 µg/inhalation pMDI
Albuterol (salbutamol) is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow.
Albuterol (salbutamol) is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow. Used for Acute relief of bronchospasm in asthma, Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD), Prevention of exercise-induced bronchospasm.
At a glance
| Generic name | Ventoline® Evohaler® 100 µg/inhalation pMDI |
|---|---|
| Also known as | Salbutamol 100 µg/dose MDI |
| Sponsor | Orion Corporation, Orion Pharma |
| Drug class | Short-acting beta-2 adrenergic agonist (SABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
The drug binds to and activates beta-2 adrenergic receptors on airway smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and bronchodilation, providing rapid symptomatic relief of airway obstruction. It is used for acute relief of asthma symptoms and as a rescue medication during acute exacerbations.
Approved indications
- Acute relief of bronchospasm in asthma
- Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD)
- Prevention of exercise-induced bronchospasm
Common side effects
- Tremor
- Headache
- Nervousness or anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs (PHASE4)
- Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: